Metyrosine

An inhibitor of tyrosine hydroxylase and therefore a powerful inhibitor of catecholamine synthesis; used for controlling the manifestations of pheochromocytoma, in preoperative preparation, or in instances where surgical resection is contraindicated or incomplete.

Brands
Adult Dose
Dose: 250 mg
Single Dose: 250 (250)
Frequency: 6 hourly
Route: PO
Instructions:
Neonatal
Paedriatic
Characteristics
. The Molecular Weight of Metyrosine is 195.22.
Contraindications
Metyrosine is contraindicated in conditions like Hypersensitivity to any component of product.
Effects
The severe or irreversible adverse effects of Metyrosine, which give rise to further complications include Peripheral edema, Eosinophilia, Eosinophilia, Extrapyramidal symptoms, Crystalluria, Transient dysoria, Haemotoria.The signs and symptoms that are produced after the acute overdosage of Metyrosine include Diarrhea, Hallucinations, Tremor, Agitation, Depression, Anxiety.The symptomatic adverse reactions produced by Metyrosine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Insomnia, Dry mouth, Confusion, Sedation, Disorientation, Nausea and vomiting, Dry mouth, Confusion.
Indications
Metyrosine is primarily indicated in conditions like pheochromocytoma, Premedication before surgery, and can also be given in adjunctive therapy as an alternative drug of choice in Schizophrenia.
Interactions
Metyrosine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholMetyrosine may add to the sedative effects of alcohol and other CNS depressants, e.g., hypnotics, sedatives, and tranquilizers.Amantadine (HCl)Theoretical potential for METIROSINE increasing the EXTRAPYRAMIDAL side effects of AMANTADINE. ModerateBaclofenTheoretical potential for BACLOFEN increasing the HYPOTENSIVE effect of METIROSINE. ModerateBetamethasoneTheoretical potential for BETAMETHASONE reducing the HYPOTENSIVE effect of METIROSINE. ModerateCarbenoxolone (Na)Theoretical potential for CARBENOXOLONE reducing the HYPOTENSIVE effect of METIROSINE. ModerateFlumethasoneTheoretical potential for FLUMETASONE reducing the HYPOTENSIVE effect of METIROSINE. ModerateHaloperidolHydrocortisoneTheoretical potential for HYDROCORTISONE reducing the HYPOTENSIVE effect of METIROSINE. ModerateMethylprednisoloneTheoretical potential for METHYLPREDNISOLONE reducing the HYPOTENSIVE effect of METIROSINE. ModerateMolindoneConcurrent use with Molindone increases certain serious side effects.Phenylbutazone Theoretical potential for PHENYLBUTAZONE reducing the HYPOTENSIVE effect of METIROSINEModerate These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Increase urinary conc. of catecholamines.
Risks
Drug should not be given to Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
When receiving Metyrosine, patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a motor vehicle or operating machinery. Metyrosine may have additive sedative effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, and tranquilizers. Patients should be advised to maintain a liberal fluid intake. Suitable laboratory tests should be carried out periodically in patients requiring prolonged use of Metyrosine and caution should be observed in patients with impaired hepatic or renal function. When Metyrosine is used preoperatively, alone or especially in combination with alpha-adrenergic blocking drugs, adequate intravascular volume must be maintained intraoperatively (especially after tumor removal) and postoperatively to avoid hypotension and decreased perfusion of vital organs resulting from vasodilatation and expanded volume capacity.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.